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Abstract: The CD52-targeting antibody alemtuzumab is established in clinical practice with 
convincing activity in relapsed and refractory chronic lymphocytic leukemia (CLL), particularly 
in patients with high-risk features and adverse prognosis. In the CAM307 study alemtuzumab 
was tested and finally approved as a first-line single agent, even though the hurdle with chlo-
rambucil as the contender was not set very high. Within clinical trials, the drug demonstrated 
an excellent ability to eliminate minimal residual disease in blood and bone marrow, which has 
been correlated with a corresponding survival advantage in patients. However, in the mainte-
nance setting, infectious complications due to severe T cell suppression have been highlighted 
and do not allow clinicans to use alemtuzumab outside of clinical trials. This review discusses 
potential therapeutic niches and future applications of alemtuzumab with a focus on CLL 
front-line treatment.
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Management issues and current practices  
in treating B-CLL
introduction
B cell chronic lymphocytic leukemia (CLL) is the most common leukemia in western 
countries with an incidence of 3 to 5 newly diagnosed patients, mostly elderly, per 
100,000 annually.1 The clinical course and prognosis of CLL is fairly variable: some 
patients live an unaffected life with stable disease for years without intervention, 
others suffer an aggressive and wasting disease course with rapid progression, arduous 
treatments and advanced death. Hence, overall survival rates in CLL range from less 
than 2 to more than 15 years (median 9 years) after diagnosis, and almost one-third 
of patients die within 5 years after disease onset.1–3 Except for allogeneic stem cell 
transplantation applicable in a small proportion of patients, no curative treatment has 
been defined for the disease.
Clinical and biological heterogeneity of CLL requires  
risk-adapted patient management  
in prospective clinical trials
The early identification of patients at high risk of an unfavorable disease course and 
the right time and choice of therapy in this particular patient group are currently the 
most delicate and unsolved challenges in CLL treatment.OncoTargets and Therapy 2010:3 54
Schweighofer and Wendtner Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
The discovery of recurrent and prognostic relevant 
chromosomal aberrations in CLL cells via conventional 
cytogenetics and fluorescence in situ hybridization (FISH) 
has introduced the stratification of CLL cases according 
to the presence or absence of genomic key abnormali-
ties.4,5 Deletions/mutations in chromosome 17p13, the site 
of the tumor suppressor TP53 (p53 gene), are associated 
with resistance or early failure after chemotherapy with or 
without the CD20-antibody rituximab and go along with the 
most decreased survival of patients.5–10 Once refractory to 
treatment based on purine analogues, such as fludarabine, 
patients belong to the worst prognostic category with a 
median overall survival of less than 12 months.11 Similarly, 
deletions/mutations in chromosome 11q22–23 (includes 
the ATM gene locus) correlate with early advanced disease, 
particular in lymph nodes, shorter time to first treatment 
and shortened long-term survival after chemotherapy.4,5,12 
Other powerful surrogate markers of an unfavorable 
prognosis are an unmutated status of the immunoglobulin 
heavy chain variable region genes (IGHV) and an elevated 
level of ZAP70 expression in CLL cells.13–15 The variety 
and variability of numerous other available biomarkers of 
prognosis reflect the clinical and biological heterogene-
ity of CLL. However, for many of these the final role for 
individual patient management and treatment decisions in 
clinical practice needs to be validated in prospective clini-
cal trials.
Front-line treatment in CLL: where do 
we stand?
In general, “watchful waiting” with therapeutic action until 
the disease becomes symptomatic, or causes progressive 
bone marrow failure or systemic malaise, has been the 
gold standard in CLL. First-line drugs, approved by regula-
tory agencies include alkylating agents like chlorambucil, 
cyclophosphamide and bendamustine, the purine analog 
fludarabine and the monoclonal CD52-antibody alemtu-
zumab. Explicit approval of the CD20-antibody rituximab 
for combined immunochemotherapy in untreated CLL has 
been given by the European Medicines Agency (EMEA) in 
February 2009. A survival benefit for CLL patients treated at 
early stage of their disease has never been shown. However, 
this has been validated only for treatment with the alkylator 
chlorambucil16 and is currently subject of clinical trials 
applying newer therapeutic options (ie, purine analog based 
chemo- or immunochemotherapy).
Single agent therapy, including alemtuzumab, achieves 
limited rates of complete remissions (10%-24%) in CLL 
(Table 1). In contrast, combination therapy based on purine 
analogues, such as fludarabine (F), has shifted the treatment 
paradigm of CLL front-line therapy from purely palliative 
treatment to treatment with intent to cure. According to a piv-
otal phase II trial at the M.D. Anderson Cancer Center (Texas, 
USA) and a randomized phase III study by the German CLL 
Study Group (GCLLSG), combined immunochemotherapy by 
fludarabine, cyclophosphamide and rituximab (FCR) is cur-
rently the most active front-line regimen and taking the lead 
as a standard in treatment-naïve patients with limited comor-
bidity:17–19 With an overall response rate (ORR) of 95%, 44% 
complete responders (CR) and progression-free survival (PFS) 
of 51.8 months, FCR was significantly better than the hitherto 
standard FC (ORR 88.4%, CR 21.7%, PFS 32.8 months) in 
the so far largest randomized trial on FCR with 817 recruited 
patients.17 Although this regimen induced significantly more 
myelosuppression than FC, particularly neutropenias, there 
was no proportional increase of infections.17–19 Major CLL 
study groups are now investigating modifications of the FCR 
regimen in order to optimize efficacy and decrease toxicity 
(ie, by dose reduction of FC, increased dose of rituximab, 
addition of mitoxantrone or alemtuzumab, replacement of the 
FC-“backbone” by bendamustine, for example).20–24
Despite the encouraging achievements by first-line 
  immunochemotherapy, available long-term follow-up data of 
the M.D. Anderson trial suggest that the majority of patients 
responding to FCR still inevitably progress at a deferred 
time.18,19 In contrast to patients with 11q abnormalities, who 
seem to benefit particularly from FCR treatment, cases with 
an unmutated IGHV gene or 17p/TP53 abnormalities – 
although they respond slightly better to FCR than to chemo-
therapy alone – continue to have an inferior response, PFS 
and overall survival (OS).19,25–27
elimination of minimal residual disease 
(MrD) increases the probability  
of long-term survival in CLL patients
Two major mechanisms might account for treatment-
  refractory disease: First, clonal selection of CLL cells 
harboring advantageous mutations or chromosomal 
deletions of tumor suppressors (such as TP53), second, 
clonal evolution of not thoroughly eradicated CLL cells 
surviving as MRD in physiologic niches.28–30 With the 
availability of standardized approaches for four-color 
flow cytometry (“MRD flow”) and PCR-based ampli-
fication of the rearranged variable region of the IGHV 
gene rearrangements (using consensus or clone specific 
primers), one single residual CLL cell can currently be OncoTargets and Therapy 2010:3 55
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tracked in 10,000 to 100,000 leukocytes of peripheral 
blood or bone marrow.31–33 The achievement of a MRD-
negative remission by flow has been correlated with 
improved progression-free and/or overall survival in 
several clinical trials. In an exemplar study by Moreton 
and colleagues, alemtuzumab was the first and only drug, 
which – given as a single agent – induced four-color 
flow-confirmed molecular remissions in correlation with 
an overall survival benefit in relapsed/refractory CLL 
patients (for details see below).34 As a result of these 
and other studies, MRD negativity has been adopted as 
a recommended trial endpoint in the recently updated 
diagnostic and treatment guidelines of the IWCLL work-
ing group.35
Table 1 Efficacy of alemtuzumab compared to other first-line single-agent regimens in chronic lymphocytic leukemia
Drug  Author  Trial 
phase
No. 
of pts
Max dose  ORR (%)a  CR (%)a  Median PFS 
(months)
Median OS 
(months)
% OS at 
n years
Alemtuzumab iv Hillmen et al59 iii 149 30 mg tiw iv, 
12 weeks
83 24 14.6 nr –
Alemtuzumab sc Lundin et al53 ii 41 30 mg tiw sc, 
18 weeks
87 19 nr nr –
Karlsson et al66 14 (TTP) 
28 (TTTF)
– –
Fludarabine iv rai et al87 iii 170 25 mg/m2 day 
1–5, q28d, 6 cycles
63 20 20 (TTP) 66 –
eichhorst et al88b iii 182 25 mg/m2 day 
1–5, q28d, 6 cycles
82.9 6.7 
18.3 uCr
20 nr 80.7 at 
3 years
Catovsky et al9 iii 181 25 mg/m2 day 
1–5 iv or 40 mg/m2 
day 1–5 po, q28d, 
6 cycles
80 15 23 – 52 at 5 years
Flinn et al89 iii 137 25 mg/m2 day 
1–5, q28d, 6 cycles
59.5 4.6 19.2 nr 80 at 2 years
eichhorst et al38c iii 87 25 mg/m2 day 
1–5, q28d, 6 cycles
72 7 19 46 –
Bendamustine iv Knauf et al90 iii 162 100 mg/m2 d1–2, 
q28d, 6 cycles
68 31 21.6 – –
Cladribine iv robak et al91 iii 126 0.12 mg/kg d1–5, 
q28d, 6 cycles
78 21 23.5 51.2 –
Chlorambucil po Hillmen 
et al59
iii 148 40 mg/m2, q28d, 
12 cycles
55 2 11.7 nr –
rai et al88 iii 181 40 mg/m2, q28d, 
12 cycles
37 4 14 (TTP) 56 –
robak et al92 iii 103 12 mg/m2 d1–7, 
6 cyclese
57 12 17 45
Catovsky et al9 iii 324 10 mg/m2 d1–7, 
12 cycles
72 7 20 – 59 at 5 years
Knauf et al90d iii 157 0.8 mg/kg d1, 
d1 + 15, 6 cycles,
31 2 8.3 – –
eichhorst et al38c iii 98 0.4 mg/kg d1, 
d1 + 15, 12 cycles, 
dose increased by 
0.1 mg/kg each 
cycle up to 
0.8 mg/kg
51 0 18 64 –
rituximab iv Hainsworth et al93 ii 44 375 mg/m2, 
1 × /week, 4 weeks
58 9 18.6 – –
aresponse assessed according to NCi Working Group Criteria 199694, binclusion limited to patients 65 years of age, cinclusion limited to patients 65 years of age, dinclusion 
limited to patients 75 years of age, eadministered in conjunction with prednisone.
Abbreviations: d, day; Cr, complete response. iv, intravenous. nr, not reached; Orr, overall response rate; OS, overall survival; PFS, progression-free survival; Pts, patients; 
q28d, administered every 28 days/4-weekly; sc, subcutaneous; TTP, time to progression; TTTF, time to treatment failure; uCR, unconfirmed CR.OncoTargets and Therapy 2010:3 56
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Future challenges in CLL front-line 
therapy
In the front-line setting, the overall goal is to further develop 
treatment regimens, which are clinically safe but maximally 
eradicate detectable disease, including MRD. Future studies 
need to focus on the pre-emptive application of powerful 
new drugs and/or maintenance and consolidation strategies, 
particularly in young high-risk patients. The rapid lymphocyte 
depleting effect of alemtuzumab appears suitable to pursue 
these goals and will be discussed in this review. Moreover, 
considerable attention on patients with high-risk disease is 
required in upcoming front-line trials.19,36,37 The evidence of 
possible clonal outgrow of CLL cells with 17p-/TP53 abnor-
malities at relapse indicates that non-eradicating treatments 
might be potentially harmful in patients with up-front presence 
of subclonal 17p-deletions or TP53 mutations.28–30 Increasing 
age and comorbidity is another future challenge to be solved: 
elderly and/or comorbid patients benefit less frequently from 
fludarabine-based chemotherapy or FCR than their younger 
counterparts with less comorbidity and need consideration in 
studies applying less aggressive treatment regimens.17,19,38
Mechanism of action, 
pharmacology/kinetics  
of alemtuzumab
Pharmacocharacteristics of alemtuzumab
Alemtuzumab (CAMPATH-1H, Campath®/MabCampath®; 
Bayer Schering Pharma, Berlin) is a fully humanized 
IgG1-type monoclonal antibody directed against CD52, 
a glycosylphosphatidylinositol-anchored cell surface gly-
coprotein expressed on human B and T cells, natural killer 
cells, eosinophils and macrophages.39,40
Originally, CAMPATH-1H was designed by Waldmann 
and colleagues for targeted depletion of normal T cells from 
donor bone marrow to combat graft-versus-host disease.41 
The relatively high density of CD52 on cells from B and 
T cell derived lymphoproliferative disorders (∼500,000 
antigen epitopes/cell) including CLL, attracted interest in 
the use of alemtuzumab as a cancer therapeutic. Normal 
hematopoietic stem cells, erythrocytes and platelets lack 
CD52 surface expression and are hence protected from 
drug-induced cytotoxicity.42,43 In contrast, neutrophils were 
recently reported to express low levels of CD52, which allow 
complement-mediated lysis and explain previously observed 
clinical neutropenias under alemtuzumab.44
The antibody kills target cells by complement- and/or 
antibody-dependent cellular cytotoxicity, but seems also to be 
capable of inducing direct apoptosis via caspase-dependent 
and -independent mechanisms.45–47
In vitro synergistic apoptotic effects of combined alemtu-
zumab plus rituximab or purine analogs have been correlated 
to complementary activities in the deregulation of pro- or 
anti-apoptotic molecules such as Bax, Bcl-2.46 Further, an 
increased surface expression of CD52 after rituximab treatment 
was observed to initiate alemtuzumab sensitivity in rituximab-
resistant cell lines.48 These observations suggest possible clini-
cal benefits from the simultaneous or sequential application of 
alemtuzumab with these or related drugs in vivo.
Clinically, the antibody reduces normal lymphocytes of 
both B- and T-lineage, resulting in a profound and occasion-
ally long-lasting lymphopenia with concomitant immunosup-
pression. This has been associated with an increased risk of 
opportunistic infections, particularly in heavily pretreated 
patients. Cytomegalovirus (CMV) reactivation is the most 
common of such events and requires careful monitoring of 
patients under alemtuzumab according to published guide-
lines.49 An anti-infective prophylaxis with cotrimoxazole 
and acyclovir or equivalent is mandatory during therapy and 
should be continued for at least 6 months after cessation of 
alemtuzumab.49
Alemtuzumab preferentially attacks CLL cells in periph-
eral blood, spleen and bone marrow, whereas bulky lymph-
adenopathy (5 cm) is less affected.34,50,51 The rapid clearance 
of CLL cells from peripheral blood and bone marrow has 
been depicted as an “in vivo purging” effect52 and occurs 
after a median treatment time of 21 days. The terminal half-
life of the antibody is estimated to be approximately 15 to 
20 days.53–55 Serum antiglobulin responses to alemtuzumab 
have been rarely (1%) observed in patients who received 
the antibody first-line and subcutaneously.56,57
recommended dosing of alemtuzumab
Different routes and schedules to administer alemtuzumab 
as monotherapy or as a combined regimen have been inves-
tigated. Usually, treatment protocols initiate dosing with a 
3-day dose escalation starting from 3 mg in order to attenuate 
first-dose reactions. Intravenous (iv) administration of alem-
tuzumab has been correlated with a higher rate of first-dose 
side effects (eg, “flu-like” symptoms, chills, rigor, hypo-
tension, nausea, vomiting, rash, urticaria, bronchospasm) 
compared to subcutaneous (sc) application, which on the 
other hand entails more convenience and the possibility of 
self-administration in an outpatient setting.50,53,58–60 A local 
injection-site erythema occurs frequently after sc applica-
tion of alemtuzumab. This side effect is normally transient, OncoTargets and Therapy 2010:3 57
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and, if clinical tolerable, may delay but should not prevent 
continued sc treatment. Both, infusion and injection-site 
related side effects usually subside with repeated applications 
of alemtuzumab.50,53,58,61
Traditionally, a 12-week regimen with 30 mg iv 3 times 
a week (tiw) has been most frequently used in CLL trials 
with alemtuzumab, but some studies have investigated other 
dose levels and treatment durations. The traditional schedule 
was designed to yield a cumulative dose around 1 g, which 
resembles the approximate target dosage required to saturate 
all CD52-antigen binding sites in an average CLL patient.43,53 
Treatment longer than 12 weeks has been correlated with 
enhanced clearance of CLL cells from bone marrow and 
improved responses, though trials comparing different 
schedules and concomitant toxicity of alemtuzumab are not 
available.53 Similarly, high maximum trough serum concen-
trations of the antibody, given tiw, have been associated with 
an improved clinical response and MRD reduction in bone 
marrow.56,62 Subcutaneous dosing is able to achieve blood con-
centrations comparable to those after iv infusion, but requires 
a longer time of drug accumulation and the application of a 
higher cumulative dose.56 However, if administered at 30 mg 
tiw for 12 weeks, sc alemtuzumab has been demonstrated to be 
not only better tolerated, but as clinically effective as iv alem-
tuzumab.57 Therefore, sc dosing of the traditional 12-week 
regimen has become the most preferred and recommended 
route of alemtuzumab monotherapy.49,57 In case of good toler-
ability and efficacy, treatment duration might be extended for 
more than 12 weeks to achieve maximum response quality at 
the discretion of the treating physician.49
Rationale for alemtuzumab: 
experience in previously treated 
CLL
Alemtuzumab is the most active single 
agent in treatment refractory  
and high risk CLL
Most available experience with alemtuzumab in CLL has 
been collected in the relapsed and/or refractory setting, 
but represents essential knowledge about clinical and 
pharmacodynamic/kinetic characteristics of the drug. One 
of the pivotal phase II trials attracting major attention to 
the efficacy of alemtuzumab was performed as salvage 
monotherapy in 93 CLL patients with inferior prognosis, 
who were refractory to fludarabine and had only few treat-
ment options.11 After 12 weeks of 30 mg alemtuzumab iv 
tiw, the ORR reached 33% with 2% complete and 31% 
partial remissions (PR). There was no difference in response 
between patients above or below the age of 70 (median age 
66, range 31–86). The median time to progression (TTP) was 
9.5 months for responders versus 4.7 months in all patients. 
Based on the results of this study, alemtuzumab acquired 
official approval in 2001 in the US and Europe for CLL 
patients, who were refractory to fludarabine or alkylating 
agents. Similar findings have recently been demonstrated 
by a German study (CLL2H, GCLLSG), applying the same 
dose schedule in 103 (109 patients enrolled) fludarabine-
refractory patients (34% ORR, 4% CR, 30% PR), however by 
a subcutaneous route of administration.57 Besides generally 
mild infusion or injection site related events, grade III/IV 
toxicity was comparable in these two trials and dominated by 
transient cytopenias (neutropenia, thrombopenia) in 50% 
of patients and infections (including CMV reactivations) in 
at least 26% of patients. The latter were mostly reversible 
and occurred less frequently in responding versus non-
responding patients, which indicated an additional impact of 
disease-related immune dysfunction for these events. Based 
on the positive experience with sc alemtuzumab in CLL2H 
and other studies, a registration trial (CAM203) for the sc 
application of the antibody in previously treated CLL has 
been initiated.
Corresponding to its activity in fludarabine-refrac-
tory patients, early studies with alemtuzumab also dem-
onstrated unexpected activity in patients with high-risk 
genetic features, particularly in chemotherapy-refractory 
patients presenting with 17p-deletions by FISH or TP53 
mutations.63,64 In this group ORR of 39% to 50% have been 
reported. The most comprehensive study on the efficacy of 
alemtuzumab monotherapy in different high-risk popula-
tions of treatment refractory high risk CLL patients was 
recently provided by Stilgenbauer and colleagues with the 
final report of the above-mentioned CLL2H trial:57 In their 
experience alemtuzumab was able to overcome the impact of 
several genetic factors of adverse prognosis, such as either 
unmutated IGHV, FISH positivity for 17p-, 11q-deletion or 
trisomy 12, or presence of TP53 mutations. ORR, median 
PFS (7.7 months) and OS (19.1 months) did not differ signifi-
cantly in patients with or without any of these abnormalities. 
ORR and OS were only significantly decreased in elderly 
patients 65 years of age and patients with a lowered ECOG 
  performance status.
Overall, published experience with alemtuzumab in 
relapsed CLL reveals unprecedented activity as a single-agent 
in both, refractory and high-risk patients. However, the reported 
number of achieved CRs is low and primarily accountable for OncoTargets and Therapy 2010:3 58
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yet unsatisfying levels of PFS and OS in these patients. To fur-
ther increase the quality and duration of remissions, especially, 
for example, in patients with bulky lymphadenopathy, clinical 
studies are underway to explore the activity of alemtuzumab 
in combination with either chemotherapy, rituximab or high 
dose steroids in front-line and salvage treatment situations 
(see alemtuzumab combinations below).
Alemtuzumab is capable of eradicating 
MrD and prolonging long-term outcome 
in CLL
Due to its rapid lymphocyte depleting effect in peripheral 
blood and bone marrow alemtuzumab has been the most 
effective single drug for the elimination of MRD in CLL 
patients. Moreton and colleagues were the first, who admin-
istered alemtuzumab monotherapy in a phase II study cohort 
of 91 heavily pretreated (44 fludarabine refractory) CLL 
patients not according to a fixed treatment schedule, but until 
the maximal possible response including MRD negativity 
was reached.34 Alemtuzumab was applied at 30 mg iv tiw 
for a median duration of 9 weeks. The length of therapy was 
directed by 4-weekly MRD levels in bone marrow as analyzed 
by four-color-flow cytometry. Grade III/IV neutropenia and 
thrombocytopenia were common hematological toxicities and 
observed in 48% and 46%, respectively. Infectious grade III 
to IV complications occurred in 33 cases (36.3%), the most 
frequent were pulmonary infections and CMV reactivations 
that all had been manageable. The ORR was 55% (36% CR 
and 19% PR). Eighteen of 49 complete responders (36.7%) 
achieved MRD negativity in bone marrow. Treatment-free 
and OS was significantly prolonged in MRD-negative patients 
compared to MRD-positive CR, PR or responders or non-
responders: in recently updated long-term data the median 
OS for all 18 MRD-negative responders had not been reached 
after a median follow up of 77 months (range 5–123 months).65 
At 72 months 66% of these patients were alive. The median 
OS for 8 fludarabine-refractory patients achieving undetect-
able MRD was determined at 87 months. At the time of 
update, 72% (13/18) of MRD-depleted CRs had not required 
any further therapy. In contrast, MRD-positive responders 
survived for a median of 56 and 42 months (CR and PR, 
respectively) compared to 14 months in non-responders.
This study clearly demonstrated the capability of alem-
tuzumab to eradicate MRD and the successful translation of 
MRD-negative remissions into a prolonged treatment-free 
and OS in CLL. Although the inclusion of fewer patients 
with bulky lymphadenopathy might explain the relatively 
high number of CRs in this usually difficult to treat trial 
population, the MRD status differentiated PFS and OS better 
than the clinically determined quality of response (CR/PR/
NR). Hence, the rate of MRD-negative remissions com-
prises an important treatment endpoint in any clinical trial 
  implementing alemtuzumab-based treatment strategies.
Efficacy and safety studies  
on alemtuzumab regimens  
with first-line potential
Alemtuzumab is one of the most active 
single agents in the CLL front-line setting
In CLL front-line treatment, encouraging ORR achieved by 
alemtuzumab were first reported by Osterborg and colleagues 
in 1996.58 In their pilot study 9 patients received first-line 
alemtuzumab, 30 mg tiw iv or sc for up to 18 weeks. 8 of 
them responded, 3 patients achieved a CR. Except one CMV-
related pneumonia, no major toxicity was observed. In an 
extended phase II study, Lundin and colleagues demonstrated 
in 41 patients that first-line alemtuzumab given sc for up to 
18 weeks (30 mg tiw) achieved an ORR of 87% including 
19% CR.53 The complete reduction of lymphadenopathy 
(29%) was significantly less frequent than complete clearance 
of CLL cells from blood (95%) and bone marrow (45%). The 
majority of patients reached best response in bone marrow 
after full completion of 18 weeks’ treatment. Twenty-one 
percent of patients developed transient grade IV neutrope-
nia, but infectious complications were rare. No bacterial 
infections, only 4 asymptomatic CMV reactivations and 1 
pneumocystis pneumonia in a patient, who did not receive 
proper prophylaxis, were reported. In an updated long-term 
analysis, the median time to treatment failure was determined 
at 28 months (range 4 to 102+ months).66
The first and only randomized phase III study (CAM307) 
addressing alemtuzumab first-line treatment compared 
alemtuzumab (30 mg iv tiw for 12 weeks) with chlorambucil 
(40 mg/m2 orally once every 28 days for up to 12 cycles) for 
front-line therapy.59 As expected, the number and quality of 
responses were significantly higher in the alemtuzumab group 
(ORR 83%, CR 24%) than in chlorambucil-treated patients 
(ORR 55%, CR 2%, P  0.0001). In terms of response, 
high-risk patients with deletions on chromosome 11 or 17, 
as detected by FISH, benefited from alemtuzumab; however 
a significant improvement in PFS could be demonstrated 
only patients with 13q deletions. Also elderly patients 
(65 years) responded significantly better to alemtuzumab 
than to chlorambucil, though again without a corresponding 
change in PFS. MRD assessment was performed in complete OncoTargets and Therapy 2010:3 59
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responders by four-color flow cytometry: Strikingly, 30% 
(11/36) of patients in CR after alemtuzumab achieved an 
MRD-negative response by four-color flow versus 0% in the 
chlorambucil arm. Both, median PFS and time to alternative 
treatment (TTT) were significantly prolonged in the alem-
tuzumab versus chlorambucil group (median PFS 14.6 ver-
sus 11.7 months, median TTT 23.3 versus 14.7 months, 
respectively). MRD-negative responders to alemtuzumab 
had a significantly longer PFS than MRD-positive. No dif-
ference in OS was seen after a fairly short median follow-up 
of 24.6 months, with 84% of patients alive in each arm. 
Significant neutropenias (46% versus 28%; P = 0.002) and 
mostly asymptomatic CMV infections (69% versus 8%) 
occurred more frequently in the alemtuzumab than in the 
chlorambucil arm; however, the overall incidence of infec-
tions (excluding CMV) did not differ. Not surprisingly, the 
results of this trial indicated the superiority of alemtuzumab 
compared to chlorambucil as first-line treatment in CLL with 
reasonable response rates and safety profile. Thrombopenias 
and infections were less frequent compared to studies in 
relapsed/refractory CLL, which corroborates an elevated risk 
of adverse events in advanced CLL patients with decreased 
bone marrow reserves and immunosurveillance. The efficacy 
of alemtuzumab at least equals, if not surpasses, the one of 
purine analogues in the CLL front-line treatment setting 
(Table 1). Therefore, the Food and Drug Administration 
(FDA) and the European Medicines Agency (EMEA) have 
recently extended their approval of alemtuzumab for untreated 
CLL (FDA). The EMEA additionally specified approval for 
those untreated patients not eligible for fludarabine-based 
combination treatment.
Alemtuzumab based combination therapy: 
The FluCam regimen and more
The in vitro observation of complementary or synergistic 
anti-leukemic drug activity, encouraged combining alemtu-
zumab with chemotherapy or other monoclonal antibodies 
(see “Pharmacocharacteristics of alemtuzumab”). Only a few 
studies investigating the efficacy of alemtuzumab combina-
tions, many in relapsed CLL, have been published to date 
and will be discussed here; however, further results of several 
phase II and randomized trials running in the first-line setting 
are pending (published data are summarized in Table 2).
In the so far largest phase II study on immunochemotherapy 
with alemtuzumab, 36 relapsed/refractory and heavily pre-
treated CLL patients (25% fludarabine refractory, range 
of treatments 1–8) received up to six 4-weekly cycles of   
“FluCam”, which consisted of fludarabine 30 mg/m2 iv 
(day 1–3) plus alemtuzumab 30 mg iv (day 1–3). The 
age range of treated patients was 38 to 80 years (median 
61.5). The overall response rate was very promising with 
83% including 30% CR and 53% PR. According to the 
Table 2 Alemtuzumab-based combinations in current clinical trials (previously untreated chronic lymphocytic leukemia)
Drug Trial identifier Author Trial Phase No. of pts Maximum dose ORR (%) CR (%)
FluCam (high risk)
or
FC (low risk)
GiMeMA
Multicenter
LLC0405
Mauro et al68 ii 74 Fludarabine 30 mg/m2 iv + 
alemtuzumab 30 mg iv, 
d1–3, q28d,4 cycles (high risk)
or
Fludarabine 30 mg/m2 iv + 
cyclophosphamide 250 mg/m2, 
d1–3, q28d, 6 cycles (low risk)
71
95
30
57
Cam-Pred 
(high-risk only)
NCri CLL206 Pettitt et al73 ii 17 Alemtuzumab 30 mg tiw up to 
16 weeks + methylprednisolone 
1.0 g/m2 d1–5 weeks 1, 5, 9, 13
n k 37
Alemtuzumab + 
rituximab at early 
stage (high-risk only)
nk Zent et al78 ii 30 Alemtuzumab 30 mg tiw + 
rituximab 375 mg/m2 qwk, 
4 weeks
90 37
Alemtuzumab + 
rituximab
nk Frankfurt et al77 ii 21 Alemtuzumab 30 mg tiw, 17 
weeks + rituximab 375 mg/m2 
every other week, 8 times
90 75
CFAr (high risk only) nk Wierda et al76 ii 60 Fludarabine 20 mg/m2 d3–5 + 
cyclophosphamide 200 mg/m2 
d3–5 + rituximab 375–500 
mg/m2 d2 + alemtuzumab 
30 mg tiw, q28d,4 cycles
94 69
Abbreviations: d, day; nk, unknown; q28d, administered every 28 days/4-weekly; qwk, administered every week; tiw, administered 3 times per week.OncoTargets and Therapy 2010:3 60
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investigators, responding patients with lymphadenopathy 
benefited particularly from synergistic activity of alemtu-
zumab and fludarabine. The median OS was 35.6 months 
for all patients and had not been reached for responders at 
the time of publication.67 The median TTP in responders 
was reported at 21.9 months compared to 12.97 months for 
all patients. Despite the dual treatment on day 1 to 3, acute 
infusion-related side effects were mild (grade I and II) and 
disappeared with repeated dosing. Grade III and IV myelo-
suppression were the most frequent adverse events, mostly 
neutropenias and thrombocytopenias in 26% and 30% of 
patients, respectively. Grade IV infections with fatal outcome 
(= final grade V) were seen in 3 patients, of whom 2 were 
refractory to both, prior therapy and FluCam (2 fungal pneu-
monias, 1 E. coli sepsis). Surprisingly, only 3 subclinical 
CMV reactivations occurred, although the majority of 
patients presented with a CMV-antiglobulin positive status 
prior to treatment.
Overall, the trial demonstrated the clinical feasibility, 
safety and efficacy of two potentially immunosuppressive 
drugs combined in one regimen, even in advanced, elderly 
or heavily pretreated and therefore immunocompromised 
patients. Infections were less frequent than expected from 
other studies with single agent alemtuzumab in advanced 
CLL. However, the relatively low cumulative dose of 
alemtuzumab in a 4- to 6-cycle FluCam regimen needs to 
be considered. Unfortunately, the study was not designed to 
assess treatment efficacy and long-term outcome in biological 
risk groups and according to MRD course. First interim data 
of a current phase III registration trial (CAM314), compar-
ing F versus FluCam in relapsed CLL, are currently being 
prepared for publication.
First-line FluCam is presumably more effective in 
high-risk patients than alemtuzumab or chemotherapy 
alone. Based on this hypothesis, an Italian multicenter trial 
(GIMEMA Multicenter LLC0405 Study) is currently inves-
tigating whether the promising activity of FluCam can be 
reiterated in untreated young CLL patients with biological 
high-risk features.68 CLL patients 60 years of age with 
advanced or progressive disease are stratified as either 
high-risk or low-risk and receive 4 courses of FluCam or 6 
cycles of FC chemotherapy, respectively. High risk patients 
are separated from low risk by the presence of either 17p-
deletion (20%), or 11q deletion plus 1, or an unmutated 
IGHV status plus 2 adverse prognostic factors (ZAP70+ 
10%, CD38+ 7%, 6q deletion or trisomy 12, unmuated 
IGHV). In case of detectable residual disease after FluCam 
by CT scan, flow cytometry and/or PCR and availability 
of a sibling donor, high risk patients continue treatment 
receiving a reduced intensity allogeneic stem cell transplant. 
Alternatively, an autologous PBSC transplant or a 12-week 
alemtuzumab consolidation can replace the allogeneic 
transplant, in case no donor is available or stem cell harvest 
is insufficient. In a first analysis, presented at the annual 
meeting of the American Hematological Society ASH 
2008,68 74 patients had been recruited, 45 treated, includ-
ing 24 high-risk patients. Seventy-one percent of high risk 
patients had responded, with 30% CR and 17% MRD nega-
tive responses. In the low risk group the ORR was 95% with 
57% CR and 19% MRD negativity. Patients refractory to 
FluCam were reported as either 17p-deleted or cases with 
bulky lymphadenopathy. As the most common toxicity, 
grade III–IV neutropenia was observed after both, FC and 
FluCam. CMV reactivation was the most frequent adverse 
event after FluCam. At the time of the report, 9 patients had 
been transplanted (3 allogeneic, 6 autologous).
The study demonstrates an appealing concept of how to 
interconnect biological risk to different levels of front-line 
treatment intensity. The choice of FC as the selected thera-
peutic regimen for low-risk patients might be questionable; 
obviously FCR would have been the recommended option 
nowadays, especially in this young and biologically “fit” 
patient population. However, first results suggest that in high-
risk patients, especially with 17p deletion, front-line FluCam 
might be as limited in activity as FCR for the number of 
achieved CRs. One reason could be the missing impact of the 
alkylator cyclophosphamide to decrease lymphadenopathy. 
However, data on long-term outcome of high-risk patients 
treated with front-line FluCam compared to FCR are needed 
to draw further conclusions.
Unfortunately, the addition of the alkylator cyclophos-
phamide to the FluCam regimen, resembling combined 
fludarabine, cyclophosphamide plus alemtuzumab (FCCam 
or FCC) has recently been found to harbor an extended risk of 
toxicity: in a study by the GCLLSG administering FCCam in 
previously treated CLL (CLL2L trial), an increased number 
of sepsis or septic shock was observed.69,70 Other phase III 
trials investigating the more aggressive triple combination 
FCCam in first-line CLL are being performed by Dutch 
(HOVON 68, FC versus FCCam in high-risk patients) and 
French study groups (CLL2007FMP, FCR versus FCCam). 
The latter has recently been prematurely terminated due to 
severe toxicity in the FCCam arm including severe infections 
with fatal outcome.71 Therefore, further intensification of the 
FluCam regimen with cyclophosphamide cannot currently 
be recommended within or outside clinical trials.OncoTargets and Therapy 2010:3 61
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Alemtuzumab plus high-dose 
corticosteroids
Based on the ability of steroids to induce p53-independent 
apoptosis and in order to amplify treatment activity in lymph 
nodes, investigators have combined alemtuzumab plus 
high-dose corticosteroids for CLL treatment.72 First data of 
the British NCRI CLL206 phase II trial were presented by 
Pettitt and colleagues at the Annual Meeting of the European 
Hematology Association 2009.73 The trial included pre- and 
non-treated patients exhibiting at least 20% of CLL cells as 
being 17p-deleted. Briefly, alemtuzumab was administered 
30 mg tiw for up to 16 weeks (4 weeks iv, followed by sc 
application) plus methylprednisolone 1.0 g/m2 day 1–5 in 
week 1, 5, 9 and 13 under a broad antimicrobial prophylaxis. 
In 39 treated patients (22 with prior therapy, 17 untreated) the 
CR/CRi35 rate was reported as overall 24% and 37% in previ-
ously untreated patients. Additionally, 3 patients achieved a 
confirmed MRD-negative CR/CRi.35 However, toxicity of this 
apparently very effective regimen was fairly high. While the 
rate of CMV infections was not increased, 41% of grade III 
to IV non-CMV infections and 38% of glucocorticoid-related 
toxicity occurred. Four patients died of infections. A full 
report with upated information on toxicity, PFS and OS has 
to be awaited to evaluate whether this regimen is clinically 
feasible. A German phase-II trial exploring the efficacy of 
alemtuzumab plus dexamethasone in patients with purine-
analog refractory disease and/or presence of 17p-deletion is 
currently ongoing (CLL2O).
FCr plus alemtuzumab – CFAr
One of the first studies investigating a combination regimen 
containing alemtuzumab in treatment-naïve patients was 
performed at the University of Texas M. D. Anderson Can-
cer Center. The trial rationale was based on the synergistic 
pro-apoptotic effect of both rituximab and alemtuzumab on 
CLL cells as confirmed in vitro.46 Simultaneous treatment 
with fludarabine, cyclophosphamide, rituximab plus alem-
tuzumab (CFAR) had first been tested in a phase II study in 
79 treatment-refractory patients, in which an ORR of 65% 
and a CR rate of 24% were observed.74 All 18 patients in 
CR presented with bone marrow free of residual disease by 
two-color flow analysis. Forty-four percent of patients with   
17p-deletion responded to CFAR. Myelosuppression was 
the most frequent toxicity.75 The same regimen (fludarabine 
20 mg/m2 day 3–5, cyclophosphamide 200 mg/m2 day 3–5; 
rituximab 375–500 mg/m2 day 2; and alemtuzumab 30 mg 
days 1, 3 and 5, 4-weekly) was subsequently tested in 
untreated high-risk patients, determined as either FISH 
positive for 17p-deletion or with a beta2-microglobulin level 
higher than twice the upper limit of normal. The data of 
59 evaluable patients (23% with 17p deletion) were recently 
updated (ASH 200976): the ORR was determined at 92% with 
70% CR. Of 14 patients with 17p-deletion, 78% responded 
and 57% achieved a CR. In a retrospective comparative 
analysis of high-risk patients treated with CFAR and matched 
historical cases treated with FCR, CFAR was associated with 
higher rates of myelosuppression, treatment discontinuation 
and CMV reactivations. There was no difference in other 
infections. However, treatment with CFAR achieved more 
frequently MRD negativity in bone marrow as assessed by 
two-color flow cytometry. With a short median follow-up 
of 24 months, no difference in time to progression or OS, 
comparing CFAR and FCR in the retrospective historical 
analysis, could be revealed.
Overall, the data suggest that CFAR is a highly active 
and surprisingly tolerable first-line regimen in high-risk CLL 
patients. It demonstrated the highest rate so far of achievable 
CRs in patients with 17p deletions; however, a corresponding 
long-term benefit in these patients is yet to become evident. 
Longer follow-up data on all 60 enrolled patients from the 
M.D. Anderson Cancer Center trial might help to determine 
the potential of CFAR within the CLL front-line algorithm. 
Given the negative experience with FCCam discussed 
above, major concerns to be clarified are whether long-term 
efficacy translates into a survival advantage with an accept-
able amount of early and late toxicity (compared to the new 
standard FCR and to FluCam), and which salvage options 
can yet be offered to patients after CFAR failure.
Alemtuzumab plus rituximab
Two studies have investigated the potential synergism of 
monoclonal antibodies rituximab and alemtuzumab with-
out any chemotherapeutic “backbone” in untreated CLL 
patients. A phase II study applying combined alemtuzumab 
and rituximab in untreated CLL patients requiring therapy 
is currently being performed by Frankfurt and colleagues, 
with first data in a small number of patients available.77 Zent 
and colleagues implemented a risk-stratified study approach 
to treat early stage CLL patients with rituximab plus alem-
tuzumab. A tailored alemtuzumab regimen of 30 mg tiw for 
4 weeks plus rituximab 375 mg/m2 once weekly was given in 
30 early stage (Rai 0-II) patients, who did not require treat-
ment according to current guidelines, but had at least one 
marker positive for high-risk disease (17p- or 11q-deletion, 
or a combination of unmutated IGHV and CD38-/ZAP70-
positivity).78 Twenty-seven of 30 patients responded, and OncoTargets and Therapy 2010:3 62
Schweighofer and Wendtner Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
11 patients achieved a CR (37%). Six patients were MRD 
negative according to three-color flow cytometry of periph-
eral blood. Toxicity was acceptable, with mainly cytopenias 
(neutropenias and monocytopenias), 3 CMV reactivations and 
1 skin infection, all of them reversible. The median duration 
of response in the 27 responders was 14.4 months, and the 
median TTP was reported at 12.5 months for all patients. 
Interestingly, the investigators repeated FISH analysis in 
patients with progressive disease and could not find evidence 
of clonal selection or evolution after treatment. In comparison 
with biologically matched historical controls, a significantly 
longer time from diagnosis to initial treatment was detected in 
patients treated with alemtuzumab plus rituximab (4.4 years) 
compared to patients who had been observed (1.9 years, 
“watch and wait”). The trial rationale addressed an unsolved 
question, namely whether single-agent monoclonal antibodies 
are able to affect the disease course and long-term outcome, 
if used in early stage CLL. Despite the presumably lower 
disease load in RAI stage 0-II patients, alemtuzumab was 
acceptably tolerated. The results are promising, but need to 
be further studied in a larger, eventually randomized, trial.
Moreover, the combination of the monoclonal antibodies 
alemtuzumab and rituximab might be useful as a front-line 
regimen in patients, who require treatment but are not suit-
able for aggressive combinations containing chemotherapy 
(ie, elderly but biologically fit, patients with intolerance of 
fludarabine, for example).
Alemtuzumab consolidation following 
front-line induction therapy
The therapeutic goal of consolidation as a treatment strategy 
is to achieve the best quality and duration of remissions on 
a morphological and molecular level. Ideally, this can be 
accomplished by shifting the response to induction treatment 
from an MRD-positive CR/PR or nodular PR to a MRD-
negative CR. Based on the concept of “in vivo purging” of 
residual disease,79 several investigators and study groups have 
tested various schedules of alemtuzumab consolidation.
Consolidation after chemotherapy
An M.D. Anderson study, one of the first using alemtuzumab 
consolidation, treated overall 58 patients in at least PR after 
remission induction by various numbers and types of treat-
ment.80 Patients received either 10 mg or 30 mg alemtuzumab 
tiw for 4 weeks. After consolidation, approximately half of the 
patients in previous PR could improve their response status 
(ORR 53%). The major reason for response failure was the 
presence of residual lymphadenopathy. Eighty-six percent of 29 
evaluable patients achieved MRD negativity by two-color flow 
cytometry, and 11/29 or 38% a molecular remission by PCR in 
bone marrow after alemtuzumab consolidation. At a median 
follow up of 18 months TTP was improved in the PCR-negative 
group compared to all other patients (median not reached ver-
sus 15 months). Grade III and IV hematological toxicity was 
more common in the 30 mg than in the 10 mg group (71% 
versus 17%). Infections occurred in 37% of patients. However, 
all of these were manageable, except 1 fatality due to fulminant 
CMV hepatitis. Interestingly, 3 patients developed an Epstein-
Barr virus-positive large cell lymphoma, which also resolved 
in all cases without any further treatment.80,81 An equivalent 
trial administering alemtuzumab 30 mg tiw sc after remission 
induction for up to 8 weeks is ongoing.81
Montillo and colleagues treated 34 patients in first remis-
sion after fludarabine-based induction (median 6 cycles 
fludarabine or FC), with alemtuzumab consolidation 10 mg 
sc tiw for 6 weeks.55 The median interval between last dose of 
induction and start of consolidation was 16 weeks (range 12 
to 76 weeks). MRD assessment was performed by consensus 
primer IGHV PCR. The CR rate improved significantly from 
35% after induction to 79.5% after alemtuzumab consolida-
tion. Whereas none of the patients had been MRD negative in 
bone marrow after fludarabine induction, 56% were in molecu-
lar remission after alemtuzumab. Side effects were notably 
rare with no major hematological toxicity, only asymptomatic 
CMV reactivations occurred. Harvest of peripheral blood stem 
cells was successfully performed in 24 of 26 patients and 18 
patients underwent subsequent autologous stem cell transplan-
tation. At a median follow up of 28 months after alemtuzumab 
17 of the 18 transplanted patients were still in CR. 9 of 16 
patients who did not undergo autologous transplantation were 
progression free at a median follow up of 17 months.
The GCLLSG conducted the only available randomized 
phase III trial addressing alemtuzumab consolidation in first 
remission after fludarabine-based treatment:82,83 CLL patients 
in CR or PR after fludarabine or fludarabine/cyclophosphamide 
chemotherapy were randomized to either receive alemtuzumab 
(30 mg iv tiw, 12 weeks) or observation with no further treat-
ment. After inclusion of 21 patients the trial had to be stopped 
prematurely due to grade III and IV infections in 7 of 11 patients 
under alemtuzumab, all of which could be successfully treated. 
After consolidation 5 of 6 patients (83%) achieved a molecular 
remission in peripheral blood confirmed by allele-specific 
primer IGHV PCR. Molecular follow up revealed sustained 
MRD reduction below 0.01% for approximately 1 year. Updated 
results with a median follow up of 48 months showed a sig-
nificantly improved PFS in the alemtuzumab arm compared to OncoTargets and Therapy 2010:3 63
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the observation cohort (10 patients, median not reached versus 
20.6 months, P = 0.0035).82
Based on this experience the GCLLSG recently launched 
a phase I/II dose escalation trial to determine the maximum 
tolerated dose (MTD) and dose-limiting toxicities (DLT) of iv 
or sc alemtuzumab for consolidation treatment.84 Additional 
safety measures have been taken in this study: patients in a 
later stage of disease, in CR or PR following second-line 
purine-analog based induction, have been included. Fur-
thermore, inclusion required a minimum interval of 90 days 
after last induction dose in order to start consolidation. 
Alemtuzumab dose escalation was started at a dose level 
of 10 mg iv/sc weekly and increased in 10 mg intervals to 
subsequent dose levels, each of them including minimally 
3 patients. First results suggest that due to 2 DLT, the MTD 
of alemtuzumab consolidation was defined at 10 mg iv in 
10 patients, a result in accordance with the data by Montillo 
and colleagues also favoring a low dose of alemtuzumab in 
the consolidation/maintenance setting.
Consolidation after 
immunochemotherapy
Unexpected high toxicity has been observed in the Cancer 
and Leukemia Group B (CALGB) initiated phase II study 
administering alemtuzumab for remission consolidation in 
CLL patients previously treated with up to 6 cycles of fluda-
rabine plus rituximab (FR) as a front-line regimen. After an 
interval of 4 months following the last dose of fludarabine, 
patients with stable disease or any remission received alem-
tuzumab consolidation with 30 mg sc tiw for 6 weeks. Safety 
data on 51 patients were first reported in 2007:85 despite 
standard Pneumocystis (PCP) and varicella zoster virus 
prophylaxis and careful monitoring for CMV reactivation, 
9 of 34 patients in PR after FR induction (26%) experienced 
unacceptable toxicity. Eight grade III toxicities (4 oppor-
tunistic infections, 3 CMV reactivations, 1 hemorrhagic 
cystitis), and 1 fatal EBV lymphoproliferative disorder were 
observed. Of 17 patients in CR after FR induction, 8 (47%) 
underwent grade III–V toxicity: 3 grade III infections   
(2 CMV , 1 Cryptococcus) and 5 fatal (grade V) infections 
(viral meningitis, Listeria meningitis, Legionella pneumonia, 
CMV and Pneumocystis pneumonia) were reported. Infec-
tions occurred during therapy or with a latency of up to 
16 months after consolidation. It was assumed, that toxicity 
of alemtuzumab was increased in complete responders due to 
less antigen availability on malignant cells after FR induction. 
The authors concluded that alemtuzumab consolidation is not 
safe in patients in CR after chemoimmunotherapy. The study 
has been amended after this experience, excluding patients 
in CR after FR induction.
Another experience in FR-treated patients was recently 
reported by Hainsworth et al86 34 patients had been treated 
after 4 cycles of FR with up to 4 weeks of 30 mg alemtuzumab 
iv tiw. Alemtuzumab was poorly tolerated with frequent 
infusion related side effects, particularly if given less than 
5 weeks after the last induction cycle. CMV infections were 
observed in 6 patients and 2 treatment-related fatalities were 
reported (1 CMV exacerbation, 1 unclear wasting syndrome). 
Also an unsatisfying response was observed in this trial: only 
5 patients went into an improved remission status (21%). 
A high frequency of residual adenopathy after induction, the 
inclusion of a fair number of SLL patients and the frequent 
abortion of alemtuzumab treatment (in 51%) were discussed 
by the authors as possible causes to explain the low response 
rate. The median PFS for all patients calculated from start of 
induction was reported at 42 months.
Overall, clinical investigation of the consolidation con-
cept in CLL confirmed a reproducible correlation between 
MRD negativity achieved by alemtuzumab therapy and 
prolonged PFS. Unfortunately, data on OS are not available 
and the only randomized trial stopped prematurely with a 
small study population. However, due to the observed toxicity 
in clinical trials, alemtuzumab consolidation after frontline 
induction cannot be recommended as a feasible approach for 
clinical practice. It is obsolete to administer alemtuzumab 
for consolidation after full induction with F(C)R-related 
immunochemotherapy. In the above-mentioned trials, recur-
rent and cumulative immunosuppression by the combined 
depletion of B cells and T cells over a relatively long period 
of time (6 months) might have contributed to the observed 
severe and life threatening infections. Also, inter-patient 
variability in biological risk, disease load and dissemina-
tion (adenopathy versus bone marrow), and in the level 
of immune reconstitution since last dose after induction, 
for example, might have effectuated adverse tolerability. 
Ongoing and future trials investigating alemtuzumab or 
alternative consolidation therapies should study carefully 
the maximum tolerable dosing, way of application, timing 
and duration of the applied consolidating regimen. Further, 
a  comprehensive clinical and molecular characterization of 
patient subsets who do or do not benefit from consolidation 
should be delivered.
Role in therapy and conclusions
In conclusion, alemtuzumab is a powerful and powerful drug 
in the arsenal of CLL therapeutics, approved for therapy of OncoTargets and Therapy 2010:3 64
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untreated and relapsed CLL. The antibody “purges” CLL cells 
in vivo very efficiently from peripheral blood and bone mar-
row and has been used successfully for MRD eradicating treat-
ment strategies. Due to the concomitant depletion of B- and 
T-lymphocytes, infectious events have been common under 
alemtuzumab and require careful monitoring, prophylaxis 
and a high standard of care in experienced and specialized 
treatment centers. In general, treatment using this antibody 
should not be employed too late in the disease course, since 
the additional disease- or age/comorbidity-related impairment 
of the immune system might increase the risk of infectious 
complications.
Alemtuzumab is one of the most effective single agents 
in CLL and a definite treatment option in relapsed/refractory 
CLL with high-risk features and inferior prognosis. Although 
the CAM307 trial has shown superiority of alemtuzumab 
versus chlorambucil in untreated patients, a putative standard 
role of alemtuzumab in first-line treatment needs to be fur-
ther elucidated, particularly in comparison to the new front-
line standard FCR. So far, only patients who are not eligible 
for FC or FCR immunochemotherapy, ie, elderly, comorbid 
but yet physically fit patients (ie, with decreased renal func-
tion) can be recommended as potentially benefiting from 
first-line alemtuzumab monotherapy. According to current 
guidelines, patients with CLL-related severe pancytopenia or 
autoimmune hemolysis resistant to conventional treatments 
may also be considered for front-line alemtuzumab.49
One flaw of the antibody is the unsatisfying activity on 
lymphadenopathy, which explains the limited rate of com-
plete responders after alemtuzumab single-agent therapy 
alemtuzumab. Therefore, major study groups are currently 
investigating combination regimens in both previously treated 
and untreated patients. Most promising are combinations with 
steroids and purine analogous (chemotherapy) or rituximab 
(chemoimmunotherapy); however, at present alemtuzumab 
combinations should be applied only within clinical trials, 
especially in the front-line setting.
High-risk CLL patients with 17p/TP53 abnormalities 
have the worst prognosis, even after FCR induction. They 
seem to benefit particularly from the p53 independent activ-
ity of alemtuzumab treatment. More studies with careful 
biological stratification and adequate clinical and biological 
long-term follow-up are required to answer whether single 
or combined treatment with alemtuzumab might be the 
approach of choice for first-line therapy in these patients. 
In addition, alternative therapies including allogeneic stem 
cell transplant and potent new agents (ie, immunomodula-
tory drugs such as lenalidomide, the cyclin-dependent kinase 
inhibitor flavopiridol, new CD20 antibodies ofatumumab 
GA101) need to be investigated in comprehensive clinical 
trials applying innovative treatment options tailored to indi-
vidual molecular profiles of disease risk and prognosis.
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